Literature DB >> 29524457

Factors Related to Nevus-Associated Cutaneous Melanoma: A Case-Case Study.

Nirmala Pandeya1, Marina Kvaskoff2, Catherine M Olsen1, Adèle C Green3, Susan Perry4, Catherine Baxter4, Marcia B Davis4, Rohan Mortimore5, Lorraine Westacott6, Dominic Wood7, Joe Triscott7, Richard Williamson5, David C Whiteman8.   

Abstract

A proportion of cutaneous melanomas display neval remnants on histologic examination. Converging lines of epidemiologic and molecular evidence suggest that melanomas arising from nevus precursors differ from melanomas arising de novo. In a large, population-based study comprising 636 cutaneous melanomas subjected to dermatopathology review, we explored the molecular, host, and environmental factors associated with the presence of neval remnants. We found that nevus-associated melanomas were significantly associated with younger age at presentation, non-brown eye color, trunk site, thickness of less than 0.5 mm, and BRAFV600E mutation. Compared with patients with de novo melanomas, those with nevus-associated tumors were more likely to self-report many moles on their skin as a teenager (odds ratio = 1.94, 95% confidence interval = 1.01-3.72) but less likely to report many facial freckles (odds ratio = 0.49, 95% confidence interval = 0.25-0.96). They also had high total nevus counts (odds ratio = 2.18, 95% confidence interval = 1.26-3.78). On histologic examination, nevus-associated melanomas exhibited less dermal elastosis in adjacent skin compared with de novo melanomas (odds ratio = 0.55, 95% confidence interval = 0.30-1.01). These epidemiologic data accord with the emerging molecular paradigm that nevus-associated melanomas arise through a distinct sequence of causal events that differ from those leading to other cutaneous melanomas.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29524457     DOI: 10.1016/j.jid.2017.12.036

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  Prevalence and clinical-pathological features of nevus-associated versus de novo melanoma: a retrospective cross-sectional study of 2806 cases.

Authors:  Michela Lai; Simonetta Piana; Giovanni Pellacani; Caterina Longo; Riccardo Pampena
Journal:  Dermatol Pract Concept       Date:  2022-04-01

2.  Dermoscopic Image Classification of Pigmented Nevus under Deep Learning and the Correlation with Pathological Features.

Authors:  Shuang Yang; Chunmei Shu; Haiyou Hu; Guanghui Ma; Min Yang
Journal:  Comput Math Methods Med       Date:  2022-05-28       Impact factor: 2.809

3.  Clinicopathological, Genetic and Survival Advantages of Naevus-associated Melanomas: A Cohort Study.

Authors:  Xavier Bosch-Amate; Sebastian Podlipnik; Constanza Riquelme-Mc Loughlin; Cristina Carrera; Alicia Barreiro-Capurro; Adriana García-Herrera; Llucia Alós; Josep Malvehy; Susana Puig
Journal:  Acta Derm Venereol       Date:  2021-03-31       Impact factor: 3.875

4.  'Mind your Moles' study: protocol of a prospective cohort study of melanocytic naevi.

Authors:  Uyen Koh; Monika Janda; Joanne F Aitken; David L Duffy; Scott Menzies; Richard A Sturm; Helmut Schaider; Brigid Betz-Stablein; Tarl Prow; H Peter Soyer; Adele C Green
Journal:  BMJ Open       Date:  2018-09-19       Impact factor: 2.692

5.  Unsupervised Phenotype-Based Clustering of Clinicopathologic Features in Cutaneous Melanoma.

Authors:  Sarem Rashid; Nikolai Klebanov; William M Lin; Hensin Tsao
Journal:  JID Innov       Date:  2021-08-20

6.  Clinical-dermoscopic similarities between atypical nevi and early stage melanoma.

Authors:  Cristina-Raluca Jitian Mihulecea; Simona Frățilă; Maria Rotaru
Journal:  Exp Ther Med       Date:  2021-06-09       Impact factor: 2.447

7.  Mutations in the BRAF, NRAS, and C-KIT Genes of Patients Diagnosed with Melanoma in Colombia Population.

Authors:  Luz D Gutiérrez-Castañeda; Mauricio Gamboa; John A Nova; Leonardo Pulido; Jose D Tovar-Parra
Journal:  Biomed Res Int       Date:  2020-07-22       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.